AU2001282005B2 - 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists - Google Patents

4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists Download PDF

Info

Publication number
AU2001282005B2
AU2001282005B2 AU2001282005A AU2001282005A AU2001282005B2 AU 2001282005 B2 AU2001282005 B2 AU 2001282005B2 AU 2001282005 A AU2001282005 A AU 2001282005A AU 2001282005 A AU2001282005 A AU 2001282005A AU 2001282005 B2 AU2001282005 B2 AU 2001282005B2
Authority
AU
Australia
Prior art keywords
methyl
compound
formula
tolyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2001282005A
Other languages
English (en)
Other versions
AU2001282005A1 (en
Inventor
Torsten Hoffmann
Patrick Schnider
Heinz Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2001282005A1 publication Critical patent/AU2001282005A1/en
Application granted granted Critical
Publication of AU2001282005B2 publication Critical patent/AU2001282005B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001282005A 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists Expired AU2001282005B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24
EP00115846.8 2000-07-24
PCT/EP2001/008432 WO2002008232A1 (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Publications (2)

Publication Number Publication Date
AU2001282005A1 AU2001282005A1 (en) 2002-05-02
AU2001282005B2 true AU2001282005B2 (en) 2006-10-19

Family

ID=8169331

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001282005A Expired AU2001282005B2 (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU8200501A Pending AU8200501A (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8200501A Pending AU8200501A (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Country Status (37)

Country Link
US (2) US6576762B2 (enExample)
EP (1) EP1305319B1 (enExample)
JP (1) JP4118673B2 (enExample)
KR (1) KR100527214B1 (enExample)
CN (1) CN1192032C (enExample)
AR (1) AR029875A1 (enExample)
AT (1) ATE322496T1 (enExample)
AU (2) AU2001282005B2 (enExample)
BR (1) BR0112695A (enExample)
CA (1) CA2416874C (enExample)
CY (1) CY1106113T1 (enExample)
CZ (1) CZ2003528A3 (enExample)
DE (1) DE60118569T2 (enExample)
DK (1) DK1305319T3 (enExample)
EC (1) ECSP034446A (enExample)
ES (1) ES2260265T3 (enExample)
GT (1) GT200100148A (enExample)
HR (1) HRP20030031A2 (enExample)
HU (1) HU229231B1 (enExample)
IL (2) IL153837A0 (enExample)
JO (1) JO2321B1 (enExample)
MA (1) MA26933A1 (enExample)
MX (1) MXPA03000367A (enExample)
MY (1) MY129224A (enExample)
NO (1) NO20030353L (enExample)
NZ (1) NZ523452A (enExample)
PA (1) PA8522801A1 (enExample)
PE (1) PE20020258A1 (enExample)
PL (1) PL366173A1 (enExample)
PT (1) PT1305319E (enExample)
RU (1) RU2276139C2 (enExample)
SI (1) SI1305319T1 (enExample)
TW (1) TWI287003B (enExample)
UY (1) UY26851A1 (enExample)
WO (1) WO2002008232A1 (enExample)
YU (1) YU2803A (enExample)
ZA (1) ZA200300219B (enExample)

Families Citing this family (23)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
ES2307925T3 (es) 2002-04-26 2008-12-01 Eli Lilly And Company Antagonistas de los receptores de la taquiquinina.
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
WO2004032875A2 (en) * 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
RU2347777C2 (ru) * 2003-07-03 2009-02-27 ะค.ะฅะพั„ั„ะผะฐะฝะฝ-ะ›ั ะ ะพัˆ ะะณ ะ”ะฒะพะนะฝั‹ะต ะฐะณะพะฝะธัั‚ั‹ nk1/nk3 ะดะปั ะปะตั‡ะตะฝะธั ัˆะธะทะพั„ั€ะตะฝะธะธ
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 ๅผ—ยทๅ“ˆๅคซๆ›ผ-ๆ‹‰็ฝ—ๅˆ‡ๆœ‰้™ๅ…ฌๅธ ็”จไฝœๅˆๆˆnk-1ๅ—ไฝ“ๆ‹ฎๆŠ—ๅ‰‚็š„ไธญ้—ดไฝ“็š„็”ฒ้…ฐ่ƒบๅกๅ•ถ่ก็”Ÿ็‰ฉ็š„ๅˆถๅค‡ๆ–นๆณ•
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ใƒŸใ‚ทใƒฃใƒญใ‚ฆใ€ใ‚ขใƒฌใ‚ฏใ‚ตใƒณใƒ€ใƒผ ๅฏพๆŠ—้ฉๅฟœใ‚’่ช˜็™บใ™ใ‚‹ใ“ใจใซใ‚ˆใ‚Š็ฅž็ตŒไผ้”็‰ฉ่ณช็ณปใ‚’่ชฟ็ฏ€ใ™ใ‚‹ๆ–นๆณ•
KR20070094666A (ko) 2005-02-25 2007-09-20 ์—ํ”„. ํ˜ธํ”„๋งŒ-๋ผ ๋กœ์Šˆ ์•„๊ฒŒ ์•ฝ์ œ ๋ฌผ์งˆ ๋ถ„์‚ฐ์„ฑ์ด ํ–ฅ์ƒ๋œ ์ •์ œ
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
MX2008014796A (es) 2006-05-31 2008-12-02 Hoffmann La Roche Derivados de aril-4-etinil-isoxazol.
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
TWI649307B (zh) 2014-05-07 2019-02-01 ๆ—ฅๅ•†ๆฉ˜็”Ÿ่—ฅๅ“ๅทฅๆฅญ่‚กไปฝๆœ‰้™ๅ…ฌๅธ Cyclohexylpyridine derivative
US10538491B2 (en) 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
CN115531553A (zh) 2015-12-22 2022-12-30 ๆญฆ็”ฐ่ฏๅ“ๅทฅไธšๆ ชๅผไผš็คพ ๅ†…ไฝ“g่›‹็™ฝ-ๅถ่”็š„ๅ—ไฝ“็š„ไธ‰้ƒจๅˆ†่ฐƒ่Š‚ๅ‰‚
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain

Citations (1)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
AU1946800A (en) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag 4-Phenyl-pyridine derivatives

Family Cites Families (12)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd ่ค‡็ด ็’ฐๅŒ–ๅˆ็‰ฉใ€ใใฎ่ฃฝ้€ ๆณ•ใŠใ‚ˆใณ็”จ้€”
KR20010041991A (ko) 1998-03-19 2001-05-25 ๋‹ค์ผ€๋‹ค ์•ผ์ฟ ํžŒ ๊ณ ๊ต ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ๋ณต์†Œํ™˜์‹ ํ™”ํ•ฉ๋ฌผ, ๊ทธ์˜ ์ œ์กฐ๋ฒ• ๋ฐ ํƒ€ํ‚คํ‚ค๋‹Œ ์ˆ˜์šฉ์ฒด๊ธธํ•ญ์•ฝ์œผ๋กœ์„œ์˜ ์šฉ๋„
TR200102490T2 (tr) * 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil tรผrevleri
KR100437587B1 (ko) * 1999-02-24 2004-06-30 ์—ํ”„. ํ˜ธํ”„๋งŒ-๋ผ ๋กœ์Šˆ ์•„๊ฒŒ 3-ํŽ˜๋‹ํ”ผ๋ฆฌ๋”˜ ์œ ๋„์ฒด ๋ฐ ๊ทธ์˜ ๋‰ด๋กœํ‚ค๋‹Œ-1 ์ˆ˜์šฉ์ฒด๊ธธํ•ญ์ œ๋กœ์„œ์˜ ์šฉ๋„
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
MXPA03000366A (es) * 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.

Patent Citations (1)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
AU1946800A (en) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
PT1305319E (pt) 2006-08-31
US6624176B2 (en) 2003-09-23
DK1305319T3 (da) 2006-08-14
CZ2003528A3 (cs) 2003-09-17
NO20030353D0 (no) 2003-01-23
CA2416874A1 (en) 2002-01-31
CN1444589A (zh) 2003-09-24
PA8522801A1 (es) 2002-09-30
EP1305319A1 (en) 2003-05-02
CA2416874C (en) 2011-01-18
ZA200300219B (en) 2004-04-08
GT200100148A (es) 2002-05-16
HK1058360A1 (en) 2004-05-14
IL153837A0 (en) 2003-07-31
ECSP034446A (es) 2003-03-10
IL153837A (en) 2008-06-05
JP4118673B2 (ja) 2008-07-16
US6576762B2 (en) 2003-06-10
YU2803A (sh) 2006-01-16
KR100527214B1 (ko) 2005-11-08
KR20030015898A (ko) 2003-02-25
HRP20030031A2 (en) 2004-02-29
WO2002008232A1 (en) 2002-01-31
ES2260265T3 (es) 2006-11-01
MY129224A (en) 2007-03-30
AU8200501A (en) 2002-02-05
MXPA03000367A (es) 2003-05-27
JO2321B1 (en) 2005-09-12
EP1305319B1 (en) 2006-04-05
HU229231B1 (en) 2013-09-30
JP2004504400A (ja) 2004-02-12
TWI287003B (en) 2007-09-21
NO20030353L (no) 2003-01-23
CN1192032C (zh) 2005-03-09
US20020038030A1 (en) 2002-03-28
DE60118569D1 (de) 2006-05-18
MA26933A1 (fr) 2004-12-20
NZ523452A (en) 2004-07-30
CY1106113T1 (el) 2011-06-08
DE60118569T2 (de) 2007-02-15
ATE322496T1 (de) 2006-04-15
HUP0301272A2 (hu) 2003-08-28
SI1305319T1 (sl) 2006-08-31
PE20020258A1 (es) 2002-04-02
US20030130508A1 (en) 2003-07-10
UY26851A1 (es) 2002-01-31
BR0112695A (pt) 2003-04-22
PL366173A1 (en) 2005-01-24
AR029875A1 (es) 2003-07-16
RU2276139C2 (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
AU2001282005B2 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
EP1035115B1 (en) 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
JP4068305B2 (ja) ๏ผ“โˆ’ใƒ•ใ‚งใƒ‹ใƒซใƒ”ใƒชใ‚ธใƒณ่ช˜ๅฐŽไฝ“ใ€ใŠใ‚ˆใณใใฎ๏ฝŽ๏ฝ‹โˆ’๏ผ‘ๅ—ๅฎนไฝ“ๆ‹ฎๆŠ—่–ฌใจใ—ใฆใฎ็”จ้€”
US6770637B2 (en) Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors
AU2001282005A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
CA2326529C (en) 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6849624B2 (en) Aromatic and heteroaromatic substituted amides
EP1856052B1 (en) Nk1 antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired